论文部分内容阅读
目的探讨HBME1和CD10免疫标记在甲状腺癌诊断中的作用。方法应用免疫组织化学方法检测82例甲状腺病变组织中HBME1和CD10的存在情况。结果正常甲状腺组织均没有HBME1和CD10的表达,良性病变没有一例HBME1和CD10同时阳性;HBME1和CD10在乳头状癌、滤泡癌、滤泡性腺瘤和结节性甲状腺肿的阳性率分别为33/35(94%)、6/7(86%)、6/20(30%)、5/20(25%)和15/35(43%)、2/7(29%)、1/20(5%)、0。两者在甲状腺癌的表达均明显高于良性病变(均P<0.001),两者在乳头状癌与滤泡癌的表达均没有明显的差异(均P>0.05)。结论HBME1和CD10免疫标记阳性提示恶性,但不表示就是乳头状癌或滤泡癌。
Objective To investigate the role of HBME1 and CD10 in the diagnosis of thyroid cancer. Methods Immunohistochemistry was used to detect the presence of HBME1 and CD10 in 82 thyroid lesions. Results None of the normal thyroid tissues expressed HBME1 and CD10. None of the benign lesions was positive for both HBME1 and CD10. The positive rates of HBME1 and CD10 in papillary carcinoma, follicular carcinoma, follicular adenoma and nodular goiter were 33 / 35 (94%), 6/7 (86%), 6/20 (30%), 5/20 (25%) and 15/35 (43%), 2/7 (29%), 1/20 (5%), 0. Both of them were significantly higher in thyroid cancer than those in benign lesions (both P <0.001). There was no significant difference between the two in papillary carcinoma and follicular carcinoma (all P> 0.05). Conclusions HBME1 and CD10 immunostaining were positive for malignancy but not for papillary or follicular carcinoma.